A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Clinical trial NCT05896059 · UNKNOWN
Trial details
- NCT number
- NCT05896059
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-15
- Primary completion
- 2024-12-31
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.